Remplir Shows Excellent Early Prostatectomy Results

Summary by 6ix AI

Orthocell Ltd has announced excellent early clinical outcomes from its Remplir product used in nerve-sparing prostate cancer surgeries, highlighting significant functional recovery in patients with advanced prostate cancer. The initial case series showed that a majority of patients experienced encouraging urinary continence and erectile function outcomes, with no complications reported during surgery or follow-up. The company plans to gather further clinical evidence to support a U.S. launch, as Remplir is already approved in multiple jurisdictions.

Written by 6ix AI from the company’s filing. How 6ix writes summaries